Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MPI | P34949 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL900773 | 0.99 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL7886328 | 0.89 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL900661 | 0.89 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL2899691 | 0.88 | MAPT (0.55) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| Hydrochloric Acid SCHEMBL3422321 | 0.88 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| Bromide SCHEMBL7147879 | 0.86 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL5108689 | 0.86 | KDM4E (0.51) | ADRA2AADRA2BADRA2CADRA1AKDM4E | |
| SCHEMBL2902371 | 0.86 | KDM4E (0.51) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| Hydrochloric Acid SCHEMBL11357932 | 0.84 | KDM4E (0.54) | ADRA2AADRA2BADRA2CADRA1AHTR1A | |
| SCHEMBL28430176 | 0.84 | ENPP2 (0.43) | ADRA2AADRA2BADRA2CADRA1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117700410-A | Preparation method of 3- (2-chloroethyl) -2-methyl-9-hydroxy-4H-pyrido [1,2-a ] pyrimidine-4-ketone | 山东康诺生物工程有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-112979643-B | 3- (2-chloroethyl) -9-hydroxy-2-methyl-4H-pyrido [1,2-a ] pyrimidin-4-one | 重庆医科大学 | 2022-05-03 | — | — | CN | claimed |
| CN-112979643-A | 3- (2-chloroethyl) -9-hydroxy-2-methyl-4H-pyrido [1,2-a ] pyrimidin-4-one | 重庆医科大学 | 2021-06-18 | — | — | CN | claimed |
| US-8481729-B2 | Processes for the preparation of paliperidone | MSN LABORATORIES LIMITED (IN) | 2013-07-09 | — | — | US | claimed |
| EP-2475663-A2 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | Actavis Group Ptc Ehf (IS) | 2012-07-18 | — | — | EP | claimed |
| US-20120164188-A1 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | ACTAVIS GROUP PTC EHF (IS) | 2012-06-28 | — | — | US | claimed |
| US-8071767-B2 | Process for preparation of 9-hydroxy-3-(2-chloroethyl)-2-methyl-4H-pyrido[1,2-A]pyrimidin-4-one hydrochloride | ACTAVIS GROUP PTC EHF (IS) | 2011-12-06 | — | — | US | claimed |
| US-20110293889-A1 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | US | claimed |
| WO-2011073997-A2 | PROCESS FOR PREPARING PALIPERIDONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-06-23 | — | — | WO | claimed |
| EP-2300467-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN Laboratories Limited (IN) | 2011-03-30 | — | — | EP | claimed |
| WO-2009116071-A2 | AN IMPROVED PROCESS FOR PREPARATION OF PALIPERIDONE | Watson Pharma Private Limited (IN) | 2009-09-24 | — | — | WO | claimed |
| EP-2046790-A2 | PROCESS FOR THE SYNTHESIS OF CMHTP AND INTERMEDIATES THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2009-04-15 | — | — | EP | claimed |
| WO-2009045489-A2 | PROCESS FOR THE SYNTHESIS OF CMHTP, A PALIPERIDONE INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-09 | — | — | WO | claimed |
| US-20090048272-A1 | PREPARATION OF PALIPERIDONE | DR. REDDY'S LABORATORIES, INC. | 2009-02-19 | — | — | US | claimed |
| WO-2008140646-A2 | PROCESS FOR THE SYNTHESIS OF CMHTP AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-11-20 | — | — | WO | claimed |
| US-20080214809-A1 | Process for the synthesis of CMHTP and intermediates thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-04 | — | — | US | claimed |
| US-20080200676-A1 | Process for the synthesis of CMHTP and intermediates thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-08-21 | — | — | US | claimed |
| WO-2008087557-A2 | AN IMPROVED PROCESS FOR PREPARATION OF 9-HYDROXY-3-(2-CHLOROETHYL)- 2-METHYL-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE HYDROCHLORIDE | ACTAVIS GROUP PTC EHF (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1924583-A2 | PROCESS FOR THE SYNTHESIS OF CMHTP AND INTERMEDIATES THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2008-05-28 | — | — | EP | claimed |
| WO-2008024415-A2 | PROCESS FOR THE SYNTHESIS OF CMHTP AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INSUSTRIES LTD. (IL) | 2008-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214809-A1 | Process for the synthesis of CMHTP and intermediates thereof | HAMP, TPMT, MPHOSPH6 | ADRA2A 1411/4885ADRA2B 1034/4885ADRA2C 1304/4885 |
| US-20090048272-A1 | PREPARATION OF PALIPERIDONE | ADCYAP1R1, AVPR2, PRLHR | ADRA2A 388/4885ADRA2B 463/4885ADRA2C 870/4885 |
| US-20080200676-A1 | Process for the synthesis of CMHTP and intermediates thereof | HAMP, DHPS, MPHOSPH6 | ADRA2A 797/4885ADRA2B 695/4885ADRA2C 1213/4885 |
| US-20110293889-A1 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | AVPR2, AVPR1B, AVPR1A | ADRA2A 503/4885ADRA2B 408/4885ADRA2C 870/4885 |
| US-20120164188-A1 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | REN, DHPS, AVPR2 | ADRA2A 359/4885ADRA2B 600/4885ADRA2C 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.